25 XP   0   0   10

FibroGen Inc
Buy, Hold or Sell?

Let's analyse Fibrogen together

PenkeI guess you are interested in FibroGen Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of FibroGen Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about FibroGen Inc

I send you an email if I find something interesting about FibroGen Inc.

Quick analysis of Fibrogen (30 sec.)










What can you expect buying and holding a share of Fibrogen? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€-1.54
Expected worth in 1 year
€-3.07
How sure are you?
21.7%

+ What do you gain per year?

Total Gains per Share
€-1.53
Return On Investment
-143.6%

For what price can you sell your share?

Current Price per Share
€1.06
Expected price per share
€0.815 - €2.4
How sure are you?
50%

1. Valuation of Fibrogen (5 min.)




Live pricePrice per Share (EOD)

€1.06

Intrinsic Value Per Share

€-18.62 - €-21.58

Total Value Per Share

€-20.17 - €-23.13

2. Growth of Fibrogen (5 min.)




Is Fibrogen growing?

Current yearPrevious yearGrowGrow %
How rich?-$162.1m$86.6m-$178.2m-194.5%

How much money is Fibrogen making?

Current yearPrevious yearGrowGrow %
Making money-$71m-$73.4m$2.3m3.3%
Net Profit Margin-193.9%-280.6%--

How much money comes from the company's main activities?

3. Financial Health of Fibrogen (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#1006 / 1016

Most Revenue
#182 / 1016

Most Profit
#935 / 1016

Most Efficient
#632 / 1016

What can you expect buying and holding a share of Fibrogen? (5 min.)

Welcome investor! Fibrogen's management wants to use your money to grow the business. In return you get a share of Fibrogen.

What can you expect buying and holding a share of Fibrogen?

First you should know what it really means to hold a share of Fibrogen. And how you can make/lose money.

Speculation

The Price per Share of Fibrogen is €1.064. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Fibrogen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Fibrogen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €-1.54. Based on the TTM, the Book Value Change Per Share is €-0.38 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.55 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Fibrogen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.57-53.5%-0.72-67.6%-0.74-69.9%-0.57-54.0%-0.52-48.8%
Usd Book Value Change Per Share-0.48-44.7%-0.41-38.2%-0.58-54.9%-0.35-32.9%-0.07-6.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.48-44.7%-0.41-38.2%-0.58-54.9%-0.35-32.9%-0.07-6.7%
Usd Price Per Share0.87-5.64-13.03-23.18-26.82-
Price to Earnings Ratio-0.38--1.83--4.45--4.63--5.97-
Price-to-Total Gains Ratio-1.82--19.27--23.06--39.33--39.05-
Price to Book Ratio-0.53--16.92--247.15--48.55--40.93-
Price-to-Total Gains Ratio-1.82--19.27--23.06--39.33--39.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.1327344
Number of shares882
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.41-0.35
Usd Total Gains Per Share-0.41-0.35
Gains per Quarter (882 shares)-358.79-308.37
Gains per Year (882 shares)-1,435.15-1,233.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1435-14450-1233-1243
20-2870-28800-2467-2476
30-4305-43150-3700-3709
40-5741-57500-4934-4942
50-7176-71850-6167-6175
60-8611-86200-7401-7408
70-10046-100550-8634-8641
80-11481-114900-9868-9874
90-12916-129250-11101-11107
100-14351-143600-12335-12340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%4.019.00.017.4%4.019.00.017.4%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%5.018.00.021.7%5.018.00.021.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.023.00.0%0.00.023.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%5.018.00.021.7%5.018.00.021.7%

Fundamentals of Fibrogen

About FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-18 02:54:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of FibroGen Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Fibrogen earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • A Net Profit Margin of -207.2% means that €-2.07 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of FibroGen Inc:

  • The MRQ is -207.2%. The company is making a huge loss. -2
  • The TTM is -193.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-207.2%TTM-193.9%-13.3%
TTM-193.9%YOY-280.6%+86.7%
TTM-193.9%5Y-272.9%+79.0%
5Y-272.9%10Y-245.2%-27.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-207.2%-199.6%-7.6%
TTM-193.9%-213.0%+19.1%
YOY-280.6%-279.3%-1.3%
5Y-272.9%-438.4%+165.5%
10Y-245.2%-605.5%+360.3%
1.1.2. Return on Assets

Shows how efficient Fibrogen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • -13.3% Return on Assets means that Fibrogen generated €-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of FibroGen Inc:

  • The MRQ is -13.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.3%TTM-14.6%+1.3%
TTM-14.6%YOY-11.2%-3.4%
TTM-14.6%5Y-8.7%-5.9%
5Y-8.7%10Y-7.8%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.3%-13.5%+0.2%
TTM-14.6%-12.9%-1.7%
YOY-11.2%-11.8%+0.6%
5Y-8.7%-14.1%+5.4%
10Y-7.8%-16.0%+8.2%
1.1.3. Return on Equity

Shows how efficient Fibrogen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • 0.0% Return on Equity means Fibrogen generated €0.00 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of FibroGen Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-114.6%+114.6%
TTM-5Y-32.1%+32.1%
5Y-32.1%10Y-28.3%-3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY-114.6%-15.1%-99.5%
5Y-32.1%-19.9%-12.2%
10Y-28.3%-20.9%-7.4%

1.2. Operating Efficiency of FibroGen Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Fibrogen is operating .

  • Measures how much profit Fibrogen makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of FibroGen Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-134.0%+134.0%
TTM-134.0%YOY-288.4%+154.5%
TTM-134.0%5Y-244.8%+110.8%
5Y-244.8%10Y-220.7%-24.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM-134.0%-225.8%+91.8%
YOY-288.4%-288.4%0.0%
5Y-244.8%-477.4%+232.6%
10Y-220.7%-625.6%+404.9%
1.2.2. Operating Ratio

Measures how efficient Fibrogen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.20 means that the operating costs are €3.20 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of FibroGen Inc:

  • The MRQ is 3.196. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.971. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.196TTM2.971+0.225
TTM2.971YOY4.063-1.092
TTM2.9715Y3.978-1.006
5Y3.97810Y3.833+0.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1963.090+0.106
TTM2.9713.264-0.293
YOY4.0633.783+0.280
5Y3.9785.679-1.701
10Y3.8337.894-4.061

1.3. Liquidity of FibroGen Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Fibrogen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.52 means the company has €1.52 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of FibroGen Inc:

  • The MRQ is 1.523. The company is able to pay all its short-term debts. +1
  • The TTM is 1.768. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.523TTM1.768-0.245
TTM1.768YOY1.976-0.208
TTM1.7685Y4.454-2.686
5Y4.45410Y4.850-0.396
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5233.914-2.391
TTM1.7684.220-2.452
YOY1.9765.388-3.412
5Y4.4546.045-1.591
10Y4.8506.406-1.556
1.3.2. Quick Ratio

Measures if Fibrogen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • A Quick Ratio of 0.62 means the company can pay off €0.62 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of FibroGen Inc:

  • The MRQ is 0.618. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.798. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.618TTM0.798-0.181
TTM0.798YOY1.120-0.322
TTM0.7985Y2.465-1.666
5Y2.46510Y2.517-0.052
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6183.572-2.954
TTM0.7983.998-3.200
YOY1.1205.390-4.270
5Y2.4655.969-3.504
10Y2.5176.287-3.770

1.4. Solvency of FibroGen Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Fibrogen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Fibrogen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.38 means that Fibrogen assets are financed with 138.3% credit (debt) and the remaining percentage (100% - 138.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of FibroGen Inc:

  • The MRQ is 1.383. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.201. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.383TTM1.201+0.182
TTM1.201YOY0.877+0.324
TTM1.2015Y0.696+0.505
5Y0.69610Y0.659+0.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3830.336+1.047
TTM1.2010.334+0.867
YOY0.8770.269+0.608
5Y0.6960.366+0.330
10Y0.6590.390+0.269
1.4.2. Debt to Equity Ratio

Measures if Fibrogen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of FibroGen Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY7.601-7.601
TTM-5Y2.161-2.161
5Y2.16110Y1.974+0.187
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM-0.396-0.396
YOY7.6010.335+7.266
5Y2.1610.434+1.727
10Y1.9740.465+1.509

2. Market Valuation of FibroGen Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Fibrogen generates.

  • Above 15 is considered overpriced but always compare Fibrogen to the Biotechnology industry mean.
  • A PE ratio of -0.38 means the investor is paying €-0.38 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of FibroGen Inc:

  • The EOD is -0.497. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.381. Based on the earnings, the company is expensive. -2
  • The TTM is -1.832. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.497MRQ-0.381-0.116
MRQ-0.381TTM-1.832+1.451
TTM-1.832YOY-4.453+2.621
TTM-1.8325Y-4.632+2.800
5Y-4.63210Y-5.970+1.338
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.497-2.259+1.762
MRQ-0.381-2.569+2.188
TTM-1.832-2.664+0.832
YOY-4.453-4.120-0.333
5Y-4.632-6.258+1.626
10Y-5.970-6.171+0.201
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of FibroGen Inc:

  • The EOD is -1.506. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.154. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.598. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.506MRQ-1.154-0.352
MRQ-1.154TTM-1.598+0.444
TTM-1.598YOY-7.032+5.435
TTM-1.5985Y-33.817+32.219
5Y-33.81710Y-29.406-4.411
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.506-2.924+1.418
MRQ-1.154-3.246+2.092
TTM-1.598-3.488+1.890
YOY-7.032-5.620-1.412
5Y-33.817-8.315-25.502
10Y-29.406-8.826-20.580
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Fibrogen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.53 means the investor is paying €-0.53 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of FibroGen Inc:

  • The EOD is -0.690. Based on the equity, the company is expensive. -2
  • The MRQ is -0.528. Based on the equity, the company is expensive. -2
  • The TTM is -16.920. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.690MRQ-0.528-0.161
MRQ-0.528TTM-16.920+16.391
TTM-16.920YOY-247.154+230.234
TTM-16.9205Y-48.551+31.632
5Y-48.55110Y-40.926-7.626
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.6901.851-2.541
MRQ-0.5282.090-2.618
TTM-16.9202.095-19.015
YOY-247.1542.844-249.998
5Y-48.5513.466-52.017
10Y-40.9263.815-44.741
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of FibroGen Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.447-0.382-15%-0.548+23%-0.328-27%-0.067-85%
Book Value Per Share---1.542-0.872-43%0.824-287%2.537-161%2.840-154%
Current Ratio--1.5231.768-14%1.976-23%4.454-66%4.850-69%
Debt To Asset Ratio--1.3831.201+15%0.877+58%0.696+99%0.659+110%
Debt To Equity Ratio----0%7.601-100%2.161-100%1.974-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.535-0.676+26%-0.698+31%-0.539+1%-0.488-9%
Free Cash Flow Per Share---0.177-0.755+327%-0.439+149%-0.319+81%-0.319+81%
Free Cash Flow To Equity Per Share---0.179-0.463+159%-0.328+83%-0.211+18%-0.211+18%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.584--------
Intrinsic Value_10Y_min---18.624--------
Intrinsic Value_1Y_max---1.982--------
Intrinsic Value_1Y_min---1.947--------
Intrinsic Value_3Y_max---6.093--------
Intrinsic Value_3Y_min---5.814--------
Intrinsic Value_5Y_max---10.371--------
Intrinsic Value_5Y_min---9.614--------
Market Cap105092556.800+23%80498528.000523314510.400-85%1208885409.600-93%2150387303.680-96%2488166771.200-97%
Net Profit Margin---2.072-1.939-6%-2.806+35%-2.729+32%-2.452+18%
Operating Margin----1.3400%-2.8840%-2.4480%-2.2070%
Operating Ratio--3.1962.971+8%4.063-21%3.978-20%3.833-17%
Pb Ratio-0.690-31%-0.528-16.920+3102%-247.154+46677%-48.551+9089%-40.926+7646%
Pe Ratio-0.497-31%-0.381-1.832+381%-4.453+1069%-4.632+1116%-5.970+1467%
Price Per Share1.064+23%0.8155.298-85%12.239-93%21.771-96%25.191-97%
Price To Free Cash Flow Ratio-1.506-31%-1.154-1.598+38%-7.032+510%-33.817+2831%-29.406+2449%
Price To Total Gains Ratio-2.381-31%-1.824-19.272+957%-23.063+1165%-39.330+2057%-39.048+2041%
Quick Ratio--0.6180.798-23%1.120-45%2.465-75%2.517-75%
Return On Assets---0.133-0.146+10%-0.112-15%-0.087-35%-0.078-41%
Return On Equity----0%-1.1460%-0.3210%-0.2830%
Total Gains Per Share---0.447-0.382-15%-0.548+23%-0.328-27%-0.067-85%
Usd Book Value---162195558.137-91646305.224-43%86636911.526-287%266761039.211-161%298654010.254-154%
Usd Book Value Change Per Share---0.476-0.407-15%-0.584+23%-0.350-27%-0.071-85%
Usd Book Value Per Share---1.642-0.928-43%0.877-287%2.701-161%3.024-154%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.569-0.719+26%-0.743+31%-0.574+1%-0.519-9%
Usd Free Cash Flow---18571605.902-79383315.450+327%-46167520.304+149%-26850630.218+45%-23348374.102+26%
Usd Free Cash Flow Per Share---0.188-0.804+327%-0.467+149%-0.340+81%-0.340+81%
Usd Free Cash Flow To Equity Per Share---0.191-0.493+159%-0.349+83%-0.224+18%-0.224+18%
Usd Market Cap111881535.969+23%85698732.909557120627.772-85%1286979407.060-93%2289302323.498-96%2648902344.620-97%
Usd Price Per Share1.133+23%0.8685.641-85%13.030-93%23.178-96%26.819-97%
Usd Profit---56230806.757-71056492.149+26%-73411942.166+31%-56707346.645+1%-51268216.413-9%
Usd Revenue--27137424.13236937216.176-27%35183003.401-23%47833634.949-43%49465341.628-45%
Usd Total Gains Per Share---0.476-0.407-15%-0.584+23%-0.350-27%-0.071-85%
 EOD+6 -2MRQTTM+11 -19YOY+17 -145Y+13 -1810Y+10 -21

3.2. Fundamental Score

Let's check the fundamental score of FibroGen Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.497
Price to Book Ratio (EOD)Between0-1-0.690
Net Profit Margin (MRQ)Greater than0-2.072
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.618
Current Ratio (MRQ)Greater than11.523
Debt to Asset Ratio (MRQ)Less than11.383
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.133
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of FibroGen Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.064
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets423,529
Total Liabilities585,728
Total Stockholder Equity-204,166
 As reported
Total Liabilities 585,728
Total Stockholder Equity+ -204,166
Total Assets = 423,529

Assets

Total Assets423,529
Total Current Assets331,559
Long-term Assets91,970
Total Current Assets
Cash And Cash Equivalents 113,688
Short-term Investments 121,898
Net Receivables 12,553
Inventory 41,565
Other Current Assets 6,711
Total Current Assets  (as reported)331,559
Total Current Assets  (calculated)296,415
+/- 35,144
Long-term Assets
Property Plant Equipment 81,219
Long Term Investments 5,290
Long-term Assets Other 5,461
Long-term Assets  (as reported)91,970
Long-term Assets  (calculated)91,970
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities217,668
Long-term Liabilities368,060
Total Stockholder Equity-204,166
Total Current Liabilities
Accounts payable 17,960
Other Current Liabilities 39,175
Total Current Liabilities  (as reported)217,668
Total Current Liabilities  (calculated)57,135
+/- 160,533
Long-term Liabilities
Long term Debt 71,934
Capital Lease Obligations Min Short Term Debt80,614
Long-term Liabilities Other 72,034
Long-term Liabilities  (as reported)368,060
Long-term Liabilities  (calculated)224,582
+/- 143,478
Total Stockholder Equity
Total Stockholder Equity (as reported)-204,166
Total Stockholder Equity (calculated)0
+/- 204,166
Other
Capital Stock988
Common Stock Shares Outstanding 98,770
Net Invested Capital -132,232
Net Working Capital 113,891
Property Plant and Equipment Gross 253,066



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
> Total Assets 
869,919
855,641
880,598
812,397
915,066
893,964
857,397
824,377
807,683
812,015
826,840
787,301
808,618
850,513
773,821
745,934
686,789
608,837
610,087
538,544
515,127
460,426
423,529
423,529460,426515,127538,544610,087608,837686,789745,934773,821850,513808,618787,301826,840812,015807,683824,377857,397893,964915,066812,397880,598855,641869,919
   > Total Current Assets 
720,083
678,783
690,015
579,000
805,791
786,480
702,490
736,405
727,168
737,484
755,110
621,694
564,466
573,399
474,059
524,415
520,643
474,224
492,826
430,549
411,357
364,108
331,559
331,559364,108411,357430,549492,826474,224520,643524,415474,059573,399564,466621,694755,110737,484727,168736,405702,490786,480805,791579,000690,015678,783720,083
       Cash And Cash Equivalents 
643,803
566,722
89,258
81,673
74,587
196,592
126,266
121,560
429,269
532,468
678,393
433,508
353,361
274,527
171,223
185,896
167,758
155,960
155,700
188,550
152,585
120,914
113,688
113,688120,914152,585188,550155,700155,960167,758185,896171,223274,527353,361433,508678,393532,468429,269121,560126,266196,59274,58781,67389,258566,722643,803
       Short-term Investments 
28,094
86,009
532,144
483,726
586,174
432,040
407,491
413,869
256,317
155,398
8,144
110,724
153,851
211,875
233,967
242,179
270,375
252,560
266,308
167,399
183,131
130,426
121,898
121,898130,426183,131167,399266,308252,560270,375242,179233,967211,875153,851110,7248,144155,398256,317413,869407,491432,040586,174483,726532,14486,00928,094
       Net Receivables 
45,189
23,187
63,684
6,023
6,453
19,225
153,665
185,098
26,519
26,252
41,883
44,573
24,266
43,994
25,401
43,883
33,573
15,328
16,299
17,654
25,599
31,694
12,553
12,55331,69425,59917,65416,29915,32833,57343,88325,40143,99424,26644,57341,88326,25226,519185,098153,66519,2256,4536,02363,68423,18745,189
       Other Current Assets 
0
0
0
0
3,899
3,652
1,717
2,203
2,052
6,014
1,807
2,523
1,309
7,090
5,070
9,390
8,038
10,426
4,353
14,490
8,863
28,500
6,711
6,71128,5008,86314,4904,35310,4268,0389,3905,0707,0901,3092,5231,8076,0142,0522,2031,7173,6523,8990000
   > Long-term Assets 
0
0
0
233,397
109,275
107,484
154,907
87,972
80,515
74,531
71,730
165,607
244,152
277,114
299,762
221,519
166,146
134,613
117,261
107,995
103,770
96,318
91,970
91,97096,318103,770107,995117,261134,613166,146221,519299,762277,114244,152165,60771,73074,53180,51587,972154,907107,484109,275233,397000
       Property Plant Equipment 
128,829
127,908
127,198
93,465
90,340
87,464
84,276
78,733
72,729
69,423
65,296
63,320
128,622
123,878
120,150
114,871
109,159
105,190
100,498
95,367
91,233
85,760
81,219
81,21985,76091,23395,367100,498105,190109,159114,871120,150123,878128,62263,32065,29669,42372,72978,73384,27687,46490,34093,465127,198127,908128,829
       Long Term Investments 
10,587
40,602
55,820
132,203
10,915
10,999
61,118
223
229
247
2,972
96,162
108,841
146,057
171,621
97,643
50,414
22,411
9,409
5,884
6,112
4,534
5,290
5,2904,5346,1125,8849,40922,41150,41497,643171,621146,057108,84196,1622,97224722922361,11810,99910,915132,20355,82040,60210,587
       Long-term Assets Other 
0
0
0
8,337
8,959
11,213
11,444
10,674
8,934
6,103
5,505
11,201
6,689
7,179
7,991
9,005
6,573
7,012
7,354
6,744
6,425
6,024
5,461
5,4616,0246,4256,7447,3547,0126,5739,0057,9917,1796,68911,2015,5056,1038,93410,67411,44411,2138,9598,337000
> Total Liabilities 
355,117
365,059
352,128
303,903
266,764
280,246
321,991
346,748
392,540
341,084
385,391
397,028
528,767
505,450
544,708
567,919
563,042
562,564
611,567
567,429
575,434
575,628
585,728
585,728575,628575,434567,429611,567562,564563,042567,919544,708505,450528,767397,028385,391341,084392,540346,748321,991280,246266,764303,903352,128365,059355,117
   > Total Current Liabilities 
90,559
100,426
89,033
93,920
82,812
87,286
102,745
66,101
77,571
118,348
163,187
167,047
232,764
209,316
225,497
255,374
240,340
251,994
273,562
254,746
194,072
209,415
217,668
217,668209,415194,072254,746273,562251,994240,340255,374225,497209,316232,764167,047163,187118,34877,57166,101102,74587,28682,81293,92089,033100,42690,559
       Short-term Debt 
0
0
0
436
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000436000
       Short Long Term Debt 
0
0
0
436
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000436000
       Accounts payable 
3,222
10,131
9,139
3,772
4,060
4,055
6,088
2,865
5,015
7,553
24,789
24,061
48,988
23,868
26,097
36,353
29,360
19,323
30,758
71,282
12,802
19,220
17,960
17,96019,22012,80271,28230,75819,32329,36036,35326,09723,86848,98824,06124,7897,5535,0152,8656,0884,0554,0603,7729,13910,1313,222
       Other Current Liabilities 
37,845
37,697
13,771
12,104
136
5,223
36,814
8,531
10,213
20,032
35,591
40,913
51,067
47,101
66,823
81,742
77,233
86,330
102,286
16,495
63,945
100,556
39,175
39,175100,55663,94516,495102,28686,33077,23381,74266,82347,10151,06740,91335,59120,03210,2138,53136,8145,22313612,10413,77137,69737,845
   > Long-term Liabilities 
0
0
0
209,983
183,952
192,960
219,246
280,647
314,969
222,736
222,204
229,981
296,003
296,134
319,211
312,545
322,702
310,570
338,005
312,683
381,362
366,213
368,060
368,060366,213381,362312,683338,005310,570322,702312,545319,211296,134296,003229,981222,204222,736314,969280,647219,246192,960183,952209,983000
       Capital Lease Obligations Min Short Term Debt
0
0
0
58,148
57,193
54,104
51,102
47,981
45,377
42,136
38,574
38,027
104,943
102,329
99,734
96,926
94,064
92,595
89,885
86,812
84,824
81,919
80,614
80,61481,91984,82486,81289,88592,59594,06496,92699,734102,329104,94338,02738,57442,13645,37747,98151,10254,10457,19358,148000
       Long-term Liabilities Other 
0
0
0
27,969
35,904
52,297
81,046
105,658
18,746
19,976
21,387
20,623
20,746
19,602
43,631
41,704
34,271
29,721
72,690
24,339
22,326
70,306
72,034
72,03470,30622,32624,33972,69029,72134,27141,70443,63119,60220,74620,62321,38719,97618,746105,65881,04652,29735,90427,969000
> Total Stockholder Equity
495,531
471,311
509,199
489,223
629,031
594,447
516,135
458,358
395,872
451,660
422,178
371,002
260,580
325,792
209,146
158,048
103,780
26,306
-21,447
-48,852
-102,274
-157,169
-204,166
-204,166-157,169-102,274-48,852-21,44726,306103,780158,048209,146325,792260,580371,002422,178451,660395,872458,358516,135594,447629,031489,223509,199471,311495,531
   Common Stock
842
848
854
861
868
872
877
889
902
909
914
921
926
927
929
933
937
939
942
966
982
983
0
0983982966942939937933929927926921914909902889877872868861854848842
   Retained Earnings Total Equity00000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
-2,611
-2,570
-2,281
-937
-462
-224
-747
1,183
-1,561
-4,256
-4,499
-4,624
-4,567
-4,158
-4,163
-6,505
-6,930
-7,346
-5,720
-4,570
-6,250
-6,923
0
0-6,923-6,250-4,570-5,720-7,346-6,930-6,505-4,163-4,158-4,567-4,624-4,499-4,256-1,5611,183-747-224-462-937-2,281-2,570-2,611



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue147,752
Cost of Revenue-18,848
Gross Profit128,904128,904
 
Operating Income (+$)
Gross Profit128,904
Operating Expense-416,961
Operating Income-269,209-288,057
 
Operating Expense (+$)
Research Development282,861
Selling General Administrative115,252
Selling And Marketing Expenses-
Operating Expense416,961398,113
 
Net Interest Income (+$)
Interest Income10,480
Interest Expense-15,532
Other Finance Cost-0
Net Interest Income-5,052
 
Pretax Income (+$)
Operating Income-269,209
Net Interest Income-5,052
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-286,867-256,603
EBIT - interestExpense = -15,532
-284,232
-268,700
Interest Expense15,532
Earnings Before Interest and Taxes (EBIT)--271,335
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-286,867
Tax Provision-3
Net Income From Continuing Ops-284,232-286,870
Net Income-284,232
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-12,6065,052
 

Technical Analysis of Fibrogen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Fibrogen. The general trend of Fibrogen is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Fibrogen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of FibroGen Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.2475 < 1.53 < 2.4.

The bearish price targets are: 1.02 > 0.815 > 0.815.

Tweet this
FibroGen Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of FibroGen Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

FibroGen Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of FibroGen Inc.

FibroGen Inc Daily Moving Average Convergence/Divergence (MACD) ChartFibroGen Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of FibroGen Inc. The current adx is .

FibroGen Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of FibroGen Inc.

FibroGen Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of FibroGen Inc.

FibroGen Inc Daily Relative Strength Index (RSI) ChartFibroGen Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of FibroGen Inc.

FibroGen Inc Daily Stochastic Oscillator ChartFibroGen Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of FibroGen Inc.

FibroGen Inc Daily Commodity Channel Index (CCI) ChartFibroGen Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of FibroGen Inc.

FibroGen Inc Daily Chande Momentum Oscillator (CMO) ChartFibroGen Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of FibroGen Inc.

FibroGen Inc Daily Williams %R ChartFibroGen Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of FibroGen Inc.

FibroGen Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of FibroGen Inc.

FibroGen Inc Daily Average True Range (ATR) ChartFibroGen Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of FibroGen Inc.

FibroGen Inc Daily On-Balance Volume (OBV) ChartFibroGen Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of FibroGen Inc.

FibroGen Inc Daily Money Flow Index (MFI) ChartFibroGen Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for FibroGen Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-25 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-16 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-19 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-19 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-20 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-25 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-17 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

FibroGen Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of FibroGen Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.064
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Fibrogen with someone you think should read this too:
  • Are you bullish or bearish on Fibrogen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Fibrogen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about FibroGen Inc

I send you an email if I find something interesting about FibroGen Inc.


Comments

How you think about this?

Leave a comment

Stay informed about FibroGen Inc.

Receive notifications about FibroGen Inc in your mailbox!